InvestorsHub Logo
Followers 0
Posts 464
Boards Moderated 0
Alias Born 09/23/2014

Re: zumantu post# 58139

Tuesday, 09/01/2015 9:06:21 AM

Tuesday, September 01, 2015 9:06:21 AM

Post# of 422598
Thanks. Seeing that Lipitor's primary Indications are Prevention Of Cardiovascular Disease and Hyperlipidemia, I imagine that Vascepa's will be Prevention Of Cardiovascular Disease and Mixed Dyslipidemia.

http://www.rxlist.com/lipitor-drug/indications-dosage.htm

Would still be nice to get Vascepa approved for use as a non-HDL-C lowering agent in the ANCHOR patient population while we are waiting for R-IT, if the FDA are not going to approve ANCHOR as a high TG lowering agent.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News